Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT13387 +/- Abiraterone in CRPC
NCT01685268Phase 2Completed
- Sponsor
- Astex Pharmaceuticals
- Start
- Sep 2012
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of onalespib in castration-resistant prostate cancer (CRPC) (4 arms), sponsored by Astex Pharmaceuticals. Primary endpoints: Safety and tolerability at 12 months and Antitumor activity (response rate) at 12 months. Started Sep 2012; status: completed.
02
Drugs
onalespib
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT01685268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01685268.